Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0041-1345(00)02022-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Existence and significance of anti-HLA-C autoantibodies to primary and persistent platelet transfusion refractoriness in patients with hematologic disorders: a retrospective study from a single centre.
Ann Med
December 2025
Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Objectives: Platelet transfusion refractoriness (PTR) is a frustrating clinical problem, and primary and persistent (P/P) PTR who experienced persistent PTR since the first transfusion was failed to be well recognized. This study aims to investigate the incidence and risk factors for P/P PTR.
Methods: Patients with hematologic disorders who underwent HLA high-resolution genotyping and donor-specific HLA antibody or panel reactive antibody (PRA) testing between January 2019 and March 2023 were reviewed.
IMPACT OF REPEAT HLA MISMATCHES ON KIDNEY GRAFT SURVIVAL: A CONTEMPORARY COLLABORATIVE TRANSPLANT STUDY (CTS) ANALYSIS.
Am J Transplant
December 2024
Institute of Immunology, Heidelberg University Hospital, Heidelberg, Germany.
Repeat HLA mismatches (RMM) have been historically associated with an increased risk of graft loss after repeat kidney transplantation, in particular HLA-DR RMM in sensitized recipients. As routine use of sensitive assays can at present prevent the transplantation of RMM in hosts with donor-specific antibodies, we hypothesized that RMM would no longer be associated with graft loss. We performed a registry analysis of the Collaborative Transplant Study database including 6711 patients who received a second kidney transplant (2 KT) between 2010 and 2021, with at least one HLA-A, -B or -DR mismatch.
View Article and Find Full Text PDFPrevalence of anti-HLA antibodies among live related renal transplant recipients: A retrospective observational study from a tertiary healthcare Center in India.
Transpl Immunol
December 2024
Department of Transfusion Medicine, Histocompatibility and Molecular Biology, Jaypee Hospital, Noida, UP 201301, India.
Aim: Detection of anti-HLA antibodies is crucial for pre-transplant histocompatibility testing, donor selection, and graft survival. The aim of this study was to evaluate the spectrum of anti-HLA antibodies among live related renal transplant recipients from one of the largest transplant centers in north India.
Methods: In this study, retrospective data of transplant workup done in past four years were analyzed using GraphPad Prism 9 Version 9.
Clinical Applicability of 2-Field High-Resolution and Extended HLA-Allele Typing in Deceased Donor Kidney Allocation.
HLA
December 2024
Department of Renal Medicine and Transplantation, Sir Charles Gairdner Hospital, Perth, Australia.
HLA-compatibility remains an important triage test for deceased donor kidney allocation. Low-intermediate resolution donor HLA-typing is typically available at allocation, but its accuracy in assigning pre-transplant donor-specific anti-HLA antibody (DSA) and HLA mismatches compared to 2-field high-resolution typing is poorly characterised. Consecutive deceased donor/recipient pairs from a single centre between 2016 and 2020 were included.
View Article and Find Full Text PDFHLA class, calcineurin inhibitor levels, and the risk of graft failure in kidney recipients with donor-specific antibodies.
Front Immunol
December 2024
Transplantation Unit, Renal Division, Department of Medicine, University Health Center (CHU) of Quebec, Faculty of Medicine, Laval University, Quebec, QC, Canada.
Introduction: De novo donor-specific HLA antibody (dnDSA) are associated with poor outcomes. Whether this observation applies to both HLA class I and II dnDSA remains unclear.
Methods: We studied 1236 consecutive kidney recipients who had routine anti-HLA antibody surveillance post-transplant.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!